Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers.
Ghrelin, produced and secreted by the A-like cells of the stomach, stimulates growth hormone secretion, gastric motility, and food intake. Cysteamine inhibits the release of somatostatin and induces the formation of duodenal ulcers in rats. The present study was conducted to investigate the dynamics of ghrelin secretion in rats treated with cysteamine. Male Wistar rats (7 wk old) were administered three doses of cysteamine (400 mg/kg) orally; at 50 h after the first dose, duodenal ulcers were induced, and the plasma level of somatostatin and gastric density of somatostatin-immunoreactive cells were significantly reduced. The plasma total and active ghrelin levels were significantly higher in the cysteamine-treated rats than in the control rats, whereas the gastric ghrelin levels, number of gastric ghrelin-immunoreactive cells, and preproghrelin mRNA expression levels were significantly lower. Even at the time points of 2 and 10 h after the first dose of cysteamine, at which time no significant ulcer formation or antral neutrophil accumulation was yet noted, a significant increase in the plasma ghrelin level and decrease in the gastric ghrelin level were observed. Furthermore, although lansoprazole treatment attenuated the duodenal ulceration induced by cysteamine, the increase in the plasma level of ghrelin could still be demonstrated. Because an inverse correlation was found between the plasma ghrelin and somatostatin levels, the inhibition of somatostatin secretion may be associated with the increased ghrelin secretion. In conclusion, an increase in the plasma ghrelin level precedes the formation of duodenal ulcers in rats treated with cysteamine.
Fukuhara
Seiichiro
S
Department of Internal Medicine, Keio University School of Medicine,35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Suzuki
Hidekazu
H
Masaoka
Tatsuhiro
T
Arakawa
Mamoru
M
Hosoda
Hiroshi
H
Minegishi
Yuriko
Y
Kangawa
Kenji
K
Ishii
Hiromasa
H
Kitajima
Masaki
M
Hibi
Toshifumi
T
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D003543:Cysteamine; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism*; D005753:Gastric Mucosa / Q000378:metabolism*; D015870:Gene Expression; D054439:Ghrelin; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology; D036361:Peptide Hormones / Q000097:blood* / Q000235:genetics / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D012720:Severity of Illness Index; D013004:Somatostatin / Q000378:metabolism
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D054439:Ghrelin; D036361:Peptide Hormones; D064747:Lansoprazole; D013004:Somatostatin; D003543:Cysteamine; D009853:Omeprazole